Status

2020 analyses will be available from April 2021 onwards

Corporate Reputation of Pharma 2020

The Effectiveness of Pharma in Tackling the Covid Pandemic of 2020
– From the patient perspective

 

From 1st November 2020 to 26th February 2021, PatientView asked patient groups around the world to comment on the reputation of the pharmaceutical industry, in particular how effective companies have been in supporting patients during the Covid pandemic. The results will be published shortly in mid-April.

1,920 patient groups from across the world answered the survey

Companies included in the 2020 publications of the corporate reputation survey:

AbbVie (including Allergan) I Acorda Therapeutics I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Biogen I Boehringer Ingelheim I Bristol Myers Squibb (including Celgene) I Chiesi Farmaceutici I CSL Behring I Daiichi Sankyo I Dr Reddy’s Laboratories I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead/Kite Pharma I Grifols I Grünenthal I GSK I Horizon Therapeutics I Ipsen I Janssen I LEO Pharma I Lundbeck I Menarini I Merck & Co (MSD outside of the US) I Merck KGaA/EMD Group I Mylan I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Pierre Fabre Laboratories I Roche (Genentech in the US, Chugai in Japan) I Sandoz I Sanofi I Servier I Sun Pharma I Takeda (including Shire) I Teva I UCB I Vertex Pharmaceuticals I Vifor I ViiV Healthcare

Industry and companies were assessed for their performance at various indicators from the perspective of patient groups:

  • Performance in reaction to the Covid pandemic of 2020
  • Patient centricity
  • Quality of patient information
  • Safety provided to patients
  • Usefulness and benefits of products to patients
  • Transparency (clinical data, funding of external stakeholders, pricing policies)
  • Provision of services ‘beyond the pill’
  • Integrity
  • The quality of patient-group partnerships;
  • Patient engagement in R&D.
  • A supplementary question on Environmental, Social, and Governance’ (ESG)

The first data analysis in April 2021 will look at pharma reputation from a global viewpoint

Other reports to be released include:

6 therapy areas:
■ Autoimmune conditions [including analyses for individual autoimmune diseases]; ■ Cancer [including analyses for individual cancers]; ■ HIV/AIDS; ■ Neuroscience [including analyses for individual neurological diseases]; ■ Rare diseases [including Bleeding disorders]; and ■ Respiratory.

9 geographic regions:
■ Asia [including analyses for individual countries]; ■ Canada; ■ France; ■ Germany; ■ Global; ■ Italy; ■ Spain;■ UK; and ■ USA.

View Report Schedule